Eledon Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
Eledon Pharmaceuticals, Inc. carries a market capitalization of 233.11M, placing it among publicly traded companies globally. Its enterprise value stands at 123.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 233.11M |
| Enterprise Value | 123.09M |
Share Statistics
Eledon Pharmaceuticals, Inc. currently has 75.85M shares outstanding.
| Shares Outstanding | 75.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Eledon Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 9.54.
| PE Ratio | 9.54 |
| PS Ratio | N/A |
| PB Ratio | 5.22 |
| P/TBV Ratio | 18.87 |
| P/FCF Ratio | -3.97 |
| P/OCF Ratio | -3.97 |
Financial Position
Eledon Pharmaceuticals, Inc. maintains a current ratio of 8.44, meaning it holds 8.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.44 |
| Quick Ratio | 8.30 |
| Debt / Equity | 1.24 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -98.09 |
| Return on Assets (ROA) | -50.75 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Eledon Pharmaceuticals, Inc.'s stock has gained approximately 15.70881% over the past 52 weeks. The 50-day moving average sits at 3.63, while the 200-day moving average is 2.92.
| Beta (5Y) | N/A |
| 52-Week Price Change | 15.70881% |
| 50-Day Moving Average | 3.63 |
| 200-Day Moving Average | 2.92 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -86.39M, while operating income came in at -86.47M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -86.47M |
| Pretax Income | -78.11M |
| Net Income | -78.15M |
| EBITDA | -86.39M |
| EBIT | -86.47M |
| Earnings Per Share (EPS) | -0.88 |
Balance Sheet
Eledon Pharmaceuticals, Inc. holds 111.09M in cash and equivalents against 555,000.00 in total debt, resulting in a net debt position of -6.15M. Total book value stands at 44.76M, with working capital of 100.12M providing operational flexibility.
| Cash & Cash Equivalents | 111.09M |
| Total Debt | 555,000.00 |
| Net Debt | -6.15M |
| Equity (Book Value) | 44.76M |
| Book Value Per Share | 0.59 |
| Working Capital | 100.12M |
Cash Flow
Eledon Pharmaceuticals, Inc. produced -68.89M in operating cash flow over the past twelve months.
| Operating Cash Flow | -68.89M |
| Capital Expenditures | N/A |
| Free Cash Flow | -68.89M |
| FCF Per Share | -0.77 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -22.98 |
| FCF Yield | -25.16 |
Stock Splits
Eledon Pharmaceuticals, Inc.'s most recent stock split took place on October 5, 2020 with a 18:1 split ratio.
| Last Split Date | 10/5/2020 |
| Split Ratio | 18:1 |
Scores
Eledon Pharmaceuticals, Inc. posts an Altman Z-Score of -5.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.46 |